TLR2 and Parkinson disease: Importantly, when it was administered in mice models of PD, NPT520-34 significantly improved PD-related symptoms, reducing PK-resistant α-Syn and normalizing the levels of dopamine transporter, translocator protein, and Toll-like receptor 2.